Business Standard

Glenmark Pharmaceuticals sees potential of NONS to prevent Covid-19

The firm, which has tasted success with its oral antiviral drug favipiravir, is now betting on the NONS to drive revenues from its Covid-19 portfolio

Nasal Covid spray
Premium

Sohini Das Mumbai
Glenmark Pharmaceuticals plans to test its upcoming nitric oxide nasal spray (NONS) that it has licensed from a Canadian Biotech firm as a preventive measure for Covid-19.
 
The firm, which has tasted success with its oral antiviral drug favipiravir, is now betting on the NONS to drive revenues from its Covid-19 portfolio.
 
In the first quarter, Covid-19 revenues were a tad less than 10 per cent of Glenmark’s turnover. Favipiravir alone sold for around Rs 350 crore, boosting its India business by 57 per cent year-on-year (YoY). What’s more? Fabiflu (Glenmark’s brand of favipiravir) enjoys margins of 35

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 27 2021 | 2:48 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com